nach oben

Die Diabetologie

Erschienen in:

26.06.2017 | Typ-1-Diabetes | Einführung zum Thema

Diabetes Update 2017

Was ist neu in der Diabetologie? Welche Leitlinien müssen geändert werden?

verfasst von: Univ.-Prof. Dr. W. A. Scherbaum

Erschienen in: Die Diabetologie | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Auszug

Beim Diabetes Update im März 2017 in Mainz wurden aktuelle Informationen zum Diabetes mellitus und Neuerungen auf diesem Fachgebiet vorgetragen und diskutiert. Inzwischen ist es für die am Diabetes interessierten Kolleginnen und Kollegen schon ein Muss, dabei gewesen zu sein. In dieser Ausgabe werden vier der beim Diabetes Update referierten Themen von den entsprechenden Experten in Form von Übersichtsarbeiten dargeboten. Diese sind

Diabetes und Lipide (Prof. Dr. Klaus Parhofer, Klinikum der Ludwig Maximilian Universität München)
Nichtmedikamentöse Behandlung des Diabetes (Prof. Dr. Stephan Martin, Westdeutsches Diabetes- und Gesundheitszentrum in Düsseldorf)
Adipositas und Ernährung (Prof. Dr. Andreas Hamann, Hochtaunus-Kliniken Bad Homburg)

…

Tamayo T, Brinks R, Hoyer A et al (2016) The prevalence and incidence of diabetes in Germany. Dtsch Arztebl Int 113:177–182PubMedPubMedCentral

American Diabetes Association (2017) Classification and diagnosis of diabetes. Diabetes Care 40(Suppl 1):S11–S24CrossRef

Toledo-Corral CM, Alderete TL, Habre R et al (2016) Effects of air pollution exposure on glucose metabolism in Los Angeles minority children. Pediatr Obes. doi:10.1111/ijpo.12188 PubMed

Thiering E, Markevych I, Brüske I et al (2016) Associations of residential long-term air pollution exposures and satellite-derived greenness with insulin resistance in German adolescents. Environ Health Perspect 124:1291–1298CrossRefPubMedPubMedCentral

Eze IC, Imboden M, Kumar A et al (2016) Air pollution and diabetes association: modification by type 2 diabetes genetic risk score. Environ Int 94:263–271CrossRefPubMed

Hansen AB, Ravnsjaer L, Loft S et al (2016) Long-term exposure to fine particulate matter and incidence of diabetes in the Danish Nurse Cohort. Environ Int 91:243–250CrossRefPubMed

Wang Z, Liu M (2016) Life years lost associated with diabetes: an individually matched cohort study using the U.S. National Health Interview Survey data. Diabetes Res Clin Pract 118:69–76CrossRefPubMed

Famulla S, Hövelmann U, Fischer A et al (2016) Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose control. Diabetes Care 39:1486–1492CrossRefPubMed

Andrew KW, Trang LT, Laura P et al (2016) Duration of infusion set survival in lipohypertrophy versus nonhyperlipotrophied tissue in patients with type 1 diabetes. Diabetes Technol Ther 18:429–435CrossRef

10.

Shetty VB, Fournier PA, Davey RJ et al (2016) Effect of exercise intensity on glucose requirements to maintain euglycemia during exercise in type 1 diabetes. J Clin Endocrinol Metab 101:972–980CrossRefPubMed

11.

Bally L, Zueger T, Pasi N (2016) Accuracy of continuous monitoing during differing exercise conditions. Diabetes Res Clin Pract 112:1–5CrossRefPubMed

12.

Drazen JM, Harrington DP, McMurray JJV et al (2017) An FDA viewpoint on unique considerations for medical device clinical trials. N Engl J Med 376:1350–1357CrossRef

13.

Heinemann L, Kamann S (2016) Adhesives used for diabetes medical devices: a neglected risk with serious consequences? J Diabetes Sci Technol 10:1211–1215CrossRefPubMed

14.

Van Beers CA, DeVries JH, Kleijer SJ et al (2016) Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol 4:893–902CrossRefPubMed

15.

Bolinder J, Antuna R, Geelhoed-Duijvestijn P et al (2016) Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicenter, non-masked, randomised controlled trial. Lancet 388:2254–2263CrossRefPubMed

16.

Haak T, Hanaire H, Ajjan R et al (2016) Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 8:55–73CrossRefPubMedPubMedCentral

17.

Russell SJ, Hillard MA, Balliro C et al (2016) Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol 4:233–243CrossRefPubMedPubMedCentral

18.

Bergensthal RM, Garg S, Stuart A (2016) Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316(13):1407–1408CrossRef

19.

Tauschmann M, Allen JM, Wilinska ME et al (2016) Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomied clinical trial. Diabetes Care 39:1168–1174CrossRefPubMed

20.

Del Favero S, Boscari F, Messori M et al (2016) Randomized summer camp crossover trial in 5‑ to 9‑year-old children: outpatient wearable artificial pancreas is feasible and safe. Diabetes Care 39:1180–1185CrossRefPubMed

21.

Shah AS, Dabelea D, Fino NF et al (2016) Predictors of increased carotid intima-media thickness in youth with type 1 diabetes: The SEARCH CVD study. Diabetes Care 39:418–425CrossRefPubMed

22.

Fiorentino M, Bolignano D, Tesar V et al (2016) Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrol Dial Transplant. doi:10.1093/ndt/gfw070 PubMed

23.

Li L, Zhang X, Li Z et al (2017) Renal pathological implications in type 2 diabetes mellitus patients with renal involvement. J Diabetes Complicat 31:114–121CrossRefPubMed

24.

Klessens CQF, Woutman TD, Veraar KAM et al (2016) An autopsy study suggests that diabetic nephropathy is underdiagnosed. Kidney Int 90:149–156CrossRefPubMed

25.

Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–344CrossRefPubMed

26.

Heerspink HJL, Desai M, Jardine M et al (2017) Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28:368–375CrossRefPubMed

27.

Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–332CrossRefPubMedPubMedCentral

28.

Marso SP, Bain SC, Consoll A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844CrossRefPubMed

29.

Magulies KB, Hernandez AF, Redfield MM et al (2016) Effects of Liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316:500–508CrossRef

30.

Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):7–22CrossRef

31.

Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 342:145–153CrossRef

32.

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcome, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128CrossRefPubMed

33.

Zannad F, McMurray JJV, Krum H et al (2011) Epleronone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21CrossRefPubMed

34.

Ogawa H, Nakayama M, Morimoto T et al (2008) Low-dose Aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. A randomized controlled trial. JAMA 300(18):2134–2141CrossRefPubMed

35.

Saito Y, Okada S, Ogawa H et al (2016) Low-dose Aspirin for primary prevention of cardiovascular events inpatients with type 2 diabetes: 10-year follow-up of a randomized controlled trial. Circulation. doi:10.1161/circulationaha.116.025760 PubMedCentral

36.

https://iqtig.org/downloads/ergebnisse/qidb/2015/2016-05-25/QIDB_2015_IBDIREKT_PDF/QIDB_2015_indirekte_Leistungsbereiche/BuAw_2015_INDIREKT/bu_Gesamt_16N1-GEBH_2015.pdf. Zugegriffen: 27. Dez. 2016

37.

Colon S, Nazareth I, Petersen I (2012) A cohort study of trends in the prevalence of pregestational diabetes in pregnancy recorded in UK general practice between 1995 and 2012. BMJ Open 6(1):e009494

38.

Noctor E, Crowe C, Carmody L et al (2016) Abnormal glucose tolerance post-gestational diabetes mellitus as defined by the International Association of Diabetes and Pregnancy Study Groups criteria. Eur J Endocrinol 175:287–297CrossRefPubMed

39.

Parent B, Martopullo I, Weiss N et al (2016) Bariatric surgery in women of childbearing age, timing between an operation and birth, and associated perinatal complications. JAMA Surg. doi:10.1001/jamasurg.2016.3621 PubMed

40.

Tojesen I (2016) Birth complicatiions are more common within two years of bariatric surgery, study finds. BMJ 355:i5651CrossRef

41.

Butalia S, Gutierrez L, Lodha A et al (2016) Short- and long-term outcomes of metformin compared with insulin alone in pregnacy: a systematic review and meta-analysis. Diabet Med 34:27–36CrossRefPubMed

42.

Mohammedi K, Woodward M, Hirakawa Y et al (2016) Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes. Diabetes Care 39:1796–1803CrossRefPubMed

43.

Pickwell K, Siersma V, Kars M et al (2016) Minor amputation does not negatively afect health-related quality of life as compared with conservative treatment in patients with a diabetic foot ulcer; An observational study. Diabetes Metab Res Rev. doi:10.1002/dmrr.2867 PubMed

44.

Weber MA, Bloch M, Bakris GL et al (2016) Cardiovascular outcomes according to systolic blood pressure in patients with and without diabetes: An ACCOMPLISH substudy. J Clin Hypertens (Greenwich) 18(4):299–307CrossRef

45.

Yusuf S, Bosch J, Dagenais G et al (2016) Cholesterol lowering in intemediate-risk persons without cardiovascular disease. N Engl J Med 374(21):2021–2031CrossRefPubMed

46.

Hacke W, Donnan G, Fieschi C et al (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363(9411):768–774CrossRefPubMed

47.

Stahl CH, Lind M, Svensson AM et al (2017) Glycaemic control and excess risk of ischeamic and hemorrhagic stroke in patients with type 1 diabetes: a cohort study of 33 453 patients. J Intern Med 281:261–272CrossRefPubMed

48.

Kernan WN, Viscoli CM, Furie KL et al (2016) Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374(14):1321–1331CrossRefPubMedPubMedCentral

49.

Skiada A, Petrikkos G (2013) Cutaneous mucomycosis. Skinmed 11:155–159PubMed

50.

Mirhoseini M, Saleh N, Al Momeni A et al (2016) A study on the association of diabetic dermopathy with nephropathy and retinopathy in patients with type 2 diabetes mellitus. J Nephropathol 5:139–143CrossRefPubMedPubMedCentral

51.

Mendes AL, Miot HA, Haddad V Jr (2017) Diabetes mellitus and the skin. An Bras Dermatol 92:8–20CrossRefPubMedPubMedCentral

52.

Binder B (2016) Differentialdiagnose der Hautveränderungen an den Beinen bei CVI. Wien Med Wochenschr 166:270CrossRefPubMed

Titel: Diabetes Update 2017
Was ist neu in der Diabetologie? Welche Leitlinien müssen geändert werden?
verfasst von: Univ.-Prof. Dr. W. A. Scherbaum
Publikationsdatum: 26.06.2017
Verlag: Springer Medizin
Schlagwort: Typ-1-Diabetes
Erschienen in: Die Diabetologie / Ausgabe 5/2017
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-017-0234-6

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Hyperglykämieinduzierte Veränderungen der Thrombozytenfunktion

Magazin

Neues zur Endokrinologe

Nichtmedikamentöse Therapie des Typ-2-Diabetes: Was ist gesichert?

Adipositas: Was ist gesichert in der Therapie?

Diabetesassoziierte Nierener﻿kran﻿kung

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Diabetesassoziierte Nierenerkrankung